This is a really interesting report by Accenture Consulting on what high performers are doing right and how pharma companies can achieve sustained high performance in the future.
The good news, according to this 'the pharmaceutical industry is buoyant'.
The great news is, the whole peer group returned to growth for the first time in four years. Accenture believes that 'this growth is now forecast to accelerate in 2016 and hold over the next 5 years'.
There are of course challenges, pressure is rising to make therapeutics more affordable and more widely accepted. So, here are Accenture's 4 key finds from its recent report on what the best course of action should be for pharmaceutical companies:
1) Investors continue to reward new science
2) Growth has returned and is forecast to accelerate while margins have improved - but growth continues to be polarized at a company level
3) Affordability and market access will challenge new science as a growth driver.
4) High Performers will increasingly combine breakthrough medical science with clearly demonstrated outcomes for patients and healthcare systems.
Accenture forecast that 'sustained high performance will come from those companies that can drive operational change that can keep pace with innovation'. With a changing healthcare economy, the real challenge will be turning science into value
To read the full report please continue to the link below.
{ The hallmarks of being a High Performer
While growth is expected to accelerate in 2016, it continues to be polarized between a group of High Performers and the remaining peer group - which struggles at returning to sustainable growth. However, this innovation-driven growth comes at a cost and focus will soon be back on sliding operating margins and delivering on post launch sales expectations.
Sustained high performance will come from those companies that can drive operational change that can keep pace with innovation. Their challenge ahead will be turning science into value by developing new operating models that can deliver on the commercial promise of new launches in a changing healthcare economy.
